Search tips
Search criteria 


Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
AAPS PharmSciTech. 2001 September; 2(3): 39–47.
Published online 2001 August 26. doi:  10.1208/pt020314
PMCID: PMC2750579

Pharmaceutical development and manufacturing of a parenteral formulation of a novel antitumor agent, VNP40101M


The objective of this study was to develop and manufacture a stable parenteral formulation for Phase I clinical trials of VNP40101M (1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(2-methylamino)carbonyl] hydrazine), a novel antitumor agent. The solubility and stability of the drug was determined. Solubility studies suggested that VNP40101M exhibited poor aqueous solubility but showed appreciable solubility in nonaqueous solvents. The aqueous solubility of the drug could not be increased by adjusting the pH. At a pH above 7, basecatalyzed decomposition of VNP40101M occurred. The low octanol-water partition coefficient of 0.75 suggested poor solubility in lipophilic solvents. Based on these preformation observations, a parenteral formulation containing 10 mg/mL of VNP40101M was prepared in a solvent system consisting of 30% ethyl alcohol and 70% polyethylene glycol-300 (PEG-300). To minimize base-catalyzed hydrolytic degradation. citric acid at 0.6% concentration was included to acidify the formulation. Rubber closures, filter membranes, and liquid transfer tubing were selected on the basis of compatibility studies and absence of loss of drug the of adsorption of these components. The formulation was subjected to accelerated stability studies and dilution studies with large volume parenteral (LVP) solutions, normal saline, and 5% dextrose injection (D5W). The results of the dilution study indicated that the formulation could be diluted in these solutions up to 2 mg/mL for 8 hours without drug precipitation and degradation. Accelerated stability studies suggested that the product should be kept at 2°C to 8°C for long-term storage. The developed formulation was successfully scaled up and manufactured for use in clinical trials.

Full Text

The Full Text of this article is available as a PDF (277K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Takemura H, Urasaki Y, Yoshida A, Fukushima T, Ueda T. Simultaneous treatment with 1-ß-D Arabinofuranosylcytosine and daunorubicin induces cross resistance to both drugs due to a combination specific mechanism in HL60 cells. Cancer Res. 2001;61:172–177. [PubMed]
2. Brisco MJ, Sykes PJ, Dolman G, et al. Early resistance to therapy during induction in childhood acute lymphoblastic leukemia. Cancer Res. 2000;60:5092–5096. [PubMed]
3. Yu DS, Sun GH, Ma CP, Chang SY. Verapamil modulation of multidrug resistance in renal cell carcinoma. J Formos Med Assoc. 2000;99:311–316. [PubMed]
4. Shyam K, Cosby LA, Sartorelli AC. Synthesis and evaluation of N,N′-bis(arylsulfonyl)hydrazines as antineoplastic agents. J Med Chem. 1985;28:525–527. doi: 10.1021/jm00382a027. [PubMed] [Cross Ref]
5. Shyam K, Furubayashi R, Hrubiec RT, Sartorelli AC. 1,2-bis(arylsulfonyl)hydrazines. 2. The influence of arylsulfonyl and aralkylsulfonyl substituents on antitumor and alkylating activity. J Med Chem. 1986;29:1323–1325. doi: 10.1021/jm00157a041. [PubMed] [Cross Ref]
6. Shyam K, Hrubiec RT, Furubayashi R, Cosby LA, Sartorelli AC. 1,2-Bis(sulfonyl)hydrazines. 3. Effects of structural modification on antineoplastic activity. J Med Chem. 1987;30:2157–2161. doi: 10.1021/jm00394a040. [PubMed] [Cross Ref]
7. Shyam K, Penketh PG, Divo AA, Loomis RH, Rose WC, Sartorelli AC. Synthesis and evaluation of l-acyl-1,2-bis(methylsulfonyl)-2-(2-chloroethyl)hydrazines as antineoplastic agents. J Med Chem. 1993;36:3496–3502. doi: 10.1021/jm00075a002. [PubMed] [Cross Ref]
8. Shyam K, Penketh PG, Loomis RH, Rose WC, Srtorelli AC. Antitumor 2-(aminocarbonyl)-1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-hydrazines. J Med Chem. 1996;39:796–801. doi: 10.1021/jm9505021. [PubMed] [Cross Ref]
9. Penketh PG, Shyam K, Sartorelli AC. Comparison of DNA lesions produced by tumor-inhibitory 1,2-bis(sulfonyl)hydrazines and chloroethylnitrosoureas. Biochem Pharmacol. 2000;59:283–291. doi: 10.1016/S0006-2952(99)00328-7. [PubMed] [Cross Ref]
10. Pratviel G, Shyam K, Sartorelli AC. Cytotoxic and DNA-damaging effects of 1,2-bis(sulfonyl)hydrazines on human cells of the Mer+ and Mer-phenotype. Cancer Biochem Biophys. 1989;10:365–375. [PubMed]
11. Penketh PG, Shyam K, Sartorelli AC. Mechanisms of resistance to alkylating agents. Cancer Treat Res. 1996;87:65–81. [PubMed]
12. Finch RA, Shyam K, Penketh PG, Sartorelli AC. 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine (101M): a novel sulfonylhydrazine prodrug with broad spectrum antineoplastic activity. Cancer Res. 2001;61:3033–3038. [PubMed]
13. ICH Guideline on the validation of analytical procedures: Methodology. Food and Drug Administration. Federal Register. 1997;62:27463–27467.
14. Powell M, Nguyen T, Baloian L. Compendium of excipients for parenteral formulations. PDA J Pharm Sci Technol. 1998;52:238–311. [PubMed]
15. Mottu F, Laurent A, Rufenacht D, Doelker E. Organic solvents for pharmaceutical parenterals and embolic liquids: a review of toxicity data. PDA J Pharm Sci Technol. 2000;54:456–469. [PubMed]
16. The West Company Technical Report. 1999 002 and 1999/006.
17. Morris JM. Sterilization decision trees development and implementation. PDA J Pharm Sci Technol. 2000;54:64–68. [PubMed]
18. Krishna G, Mao J, Almassian B. Development of a parenteral formulation of an investigational anticancer drug, 3-aminopyridine-2-carboxaldehyde thiosemicarbzone. Pharm Dev Technol. 1990;4:71–80. [PubMed]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists